Tracing the Treatment Journey Using Real-World Data
Like the pharmaceutical industry as a whole, the market research and business intelligence functions within have experienced a tremendous... In DRG Blog/ September, 2019 Ophthalmology on a Roll: Key U.S. Market Events in May 2019
New product launches, product acquisitions, and life-cycle management strategies for existing products (e.g., expansion into related indication)... In DRG Blog/ May, 2019 Eylea and the Diabetic Macular Edema Market: What Lies Ahead?
Diabetic macular edema (DME) occurs in patients with diabetes as a consequence of diabetic retinopathy and is typically referred to as the leading... In DRG Blog/ December, 2018 What Are the Opportunities and Challenges to Drug Development for Diabetic Retinopathy?
Diabetic retinopathy (DR) occurs as a consequence of diabetes and is the leading cause of visual impairment and blindness among the working-age... In DRG Blog/ December, 2018 New Drugs Could Add $8 Billion to the Migraine Market
The migraine market stands at the brink of transformation. In the much talked about prevention space, three anti-CGRP MAbs—Aimovig, Ajovy, and... In DRG Blog/ November, 2018 M&A in Robotic Surgery: Medtronic Acquires Mazor Robotics
Only a few weeks ago, in our blog on Stryker’s acquisition of K2M, we wondered whether Mazor Robotics would ever make an appearance in M&A... In DRG Blog, MedTech/ October, 2018 Forecasting the Market Impact of Generic Xeljanz
What are the most important factors to consider when forecasting the launch of generic Xeljanz? Pfizer’s Xeljanz was the first Janus kinase (Jak... In DRG Blog, MedTech/ September, 2018 7 Points on Stryker’s Acquisition of K2M
Stryker’s acquisition of K2M is consistent with the company’s recent M&A track record. With acquisitions of Entellus Medical, Novadaq, and... In DRG Blog, MedTech/ September, 2018 Allergan's Abicipar Pegol: A New Treatment Option for Wet AMD?
Abicipar Pegol Is Non-Inferior to Lucentis With Less-Frequent Dosing in Wet AMD, But May Have Safety Concerns. What Does This Mean for Wet AMD?... In DRG Blog, MedTech/ July, 2018 Select Highlights from EULAR 2018
JAK Inhibitors and Biosimilars The 19th Annual European League Against Rheumatism (EULAR) congress concluded its four-day event on June 16, 2018 in... In DRG Blog, MedTech/ July, 2018 Real-World Evidence Reveals Low Dosing Compliance in Multiple Myeloma
An Examination of Patient Data in Japan The transformation of treatment paradigms in oncology continues unabated as the last two decades saw an... In DRG Blog, MedTech/ June, 2018 What Can We Learn About Treatment Sequencing In Oncology Using RWD?
Over the last two decades, the treatment paradigm for many cancer indications has been transformed beyond recognition. To fully appreciate the... In DRG Blog, MedTech/ April, 2018 European Union Cooperation for HTA and Market Access
At the end of January 2018, the European Commission released a legislative proposal for ratification by the European Parliament and Council aimed... In DRG Blog, MedTech/ February, 2018 Will an Effective Drug Ever Reach the Market for Geographic Atrophy?
Roche/Genentech’s lampalizumab fails Phase III development for geographic atrophy Genentech reported on November 9, 2017 that lampalizumab failed... In DRG Blog, MedTech/ November, 2017 More Intravenous Therapies for Psoriatic Arthritis
Lessons from the RA market (claims data analysis) The second half of 2017 has seen FDA approvals of two intravenous (IV) therapies, i.e., BMS’s... In DRG Blog, MedTech, Digital Innovation, Drug Watch/ November, 2017 Leader, Mentor, Maverick, Friend: Celebrating the Life of Sarah Fuller
The DRG family is coming to terms this month with the loss of one of its most beloved and influential leaders. Sarah W. Fuller, who co-founded... In DRG Blog, MedTech, Digital Innovation, Drug Watch/ November, 2017 ITCA-650’s Opportunity in the Type 2 Diabetes Market
ITCA-650, a subdermal osmotic implant that provides continuous delivery of exenatide, is being developed by Intarcia Therapeutics for the treatment... In DRG Blog, MedTech, Digital Innovation, Drug Watch/ November, 2017 The Osteoporosis Market is Set to Increase to $9.1 billion in 2026
Patients with osteoporosis are at increased risk of suffering fractures due to a loss in bone strength. These fractures place a considerable burden... In DRG Blog, MedTech, Digital Innovation, Drug Watch/ November, 2017 Stability Swings Back to State-Run Exchanges
For health exchanges, stability has swung around the markets like a pendulum. At first, drastic problems with Healthcare.gov affirmed the decision... In DRG Blog, MedTech, Digital Innovation, Drug Watch/ November, 2017 Trump and Republicans Lose Big on Election Night
President Donald Trump and the Republicans took a beating in the November 2017 elections, and healthcare was at the forefront. Democrats were... In DRG Blog, MedTech, Digital Innovation, Drug Watch/ November, 2017